A-to-I RNA editing and m⁶A modification modulating expression of drug-metabolizing enzymes

Masataka Nakano and Miki Nakajima

Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920–1192, Japan (Ma N, Mi N); WPI Nano Life Science Institute (WPI-NanoLSI) Kanazawa University, Kakuma-machi, Kanazawa 920–1192, Japan (Ma N, Mi N)

Running title: Posttranscriptional modifications regulating drug metabolism

To whom all correspondence should be addressed:

Masataka Nakano and Miki Nakajima, Ph.D.

Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences; WPI

Nano Life Science Institute (WPI-NanoLSI), Kanazawa University

Kakuma-machi, Kanazawa 920–1192, Japan

E-mail: mnakano@staff.kanazawa-u.ac.jp and nmiki@p.kanazawa-u.ac.jp

Tel +81–76–234–4408

Fax +81–76–264–6282

The number of text pages: 39

The number of tables: 2

The number of figures: 4

The number of references: 125

The number of words in the Abstract: 101

The number of words in the Introduction: 288

The number of words in the Conclusion: 618

Abbreviations

ADAR, adenosine deaminase acting on RNA; AhR, aryl hydrocarbon receptor; A-to-I, adenosine-to-inosine; ALKBH5, alkB homolog 5; Arnt, aryl hydrocarbon receptor nuclear translocator; CAR, constitutive androstane receptor; CES, carboxylesterase; CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin; CSE, cigarette smoke extract; CYP, cytochrome P450; DAA, 3-deazaadenosine; DGCR8, DiGeorge syndrome critical region 8; DHFR, dihydrofolate reductase; FTO, fat mass and obesity-associated; hm⁵C, 5-hydroxymethylcytosine; HNF4 α , hepatocyte nuclear factor 4 α ; m¹A, N¹-methyladenosine; m⁶A, N⁶-methyladenosine; m⁶Am, N⁶,2'-O-dimethyladenosine; m⁵C, 5-methylcytosine;

METTL, methyltransferase-like; miRNA, microRNA; P450, cytochrome P450; PPAR α , peroxisome proliferator-activator α ; Pre-miRNA, precursor miRNA; Pri-miRNA, primary microRNA; PXR, pregnane X receptor; RXR α , retinoid X receptor α ; SAM, *S*-adenosylmethionine; TRBP, TAR RNA binding protein; UGT, UDP-glucuronosyltransferase; UTR, untranslated region; WTAP, Wilms tumor 1-associated protein; YTH, YT521-B homology

Abstract

Interindividual differences in the expression and activity of drug-metabolizing enzymes including cytochrome P450, UDP-glucuronosyltransferase, and esterases cause variable therapeutic efficacy or adverse events of drugs. As the major mechanisms causing the variability in the expression of drug-metabolizing enzymes, transcriptional regulation by transcription factors, epigenetic regulation including DNA methylation, and posttranscriptional regulation by microRNA are well known. Recently, adenosine-to-inosine RNA editing and methylation of adenosine at the N^6 position on RNA have emerged as novel regulators of drug metabolism potency. In this review article, the current knowledge of these two prevalent types of posttranscriptional modification-mediated modulation of drug metabolism-involved genes is introduced.

Significance statement

Elucidation of the significance of A-to-I RNA editing and m⁶A in the regulation of drug-metabolizing enzymes is expected to lead to a deeper understanding of interindividual variability in the therapeutic efficacy or adverse effects of medicines.

1. Introduction

There are large interindividual differences in the expression and activity of drug-metabolizing enzymes including cytochrome P450 (CYP, P450), UDP-glucuronosyltransferase (UGT), and esterases, causing variable therapeutic efficacy or adverse events of drugs. The expression of drug-metabolizing enzymes is regulated in each step, transferring genetic information from genomic DNA to RNA and then to protein. Transcriptional regulation by transcription factors including aryl hydrocarbon receptor (AhR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), and hepatocyte nuclear factor 4 α (HNF4 α) is widely known (Zanger and Schwab, 2013). As well as such transcriptional regulation, posttranscriptional regulation has been recognized to contribute to interindividual differences in the expression of drug-metabolizing enzymes. In the past decade, it became apparent that microRNAs (miRNAs), endogenous ~22-nucleotide noncoding RNAs, posttranscriptionally modulate the expression of P450, UGT, and related transcription factors, and their significance in interindividual differences in drug-metabolizing enzyme expression has been broadly recognized (Nakano and Nakajima, 2018a; Li et al., 2019).

In addition to posttranscriptional regulation by trans-acting factors such as miRNAs and RNA binding proteins, hundreds of distinct posttranscriptional modifications contribute to the regulation of the expression and function of proteins (Fu et al., 2014; Boccaletto et al., 2018). Two prevalent types of RNA modifications are adenosine-to-inosine (A-to-I) RNA editing and methylation of adenosine at the N^6 position (m^6A modification), which are observed in 38% and 25% of human genes (Picardi et al., 2017; Zhang et al., 2021). These epitranscriptomic regulations can modulate RNA processing, affecting protein expression and function (Nishikura, 2016; Maity and Das, 2016). Recently, we demonstrated that A-to-I RNA editing and m^6A modification modulate the expression of drug-metabolizing enzymes, including P450, UGT and esterase. This review describes the current knowledge of these posttranscriptional modifications and their significance in the regulation of drug metabolism.

2. A-to-I RNA editing

In 1987, a phenomenon in which double-stranded RNA (dsRNA) is unwound was found in *Xenopus laevis* oocytes and embryos (Bass and Weintraub, 1987). Later, this phenomenon was found to be caused by hydrolytic deamination of adenosine to convert to inosine, which occurs in human cells as well as *Xenopus laevis* (Bass and Weintraub, 1988; Wagner et al., 1989). The nucleotide change named A-to-I RNA editing has been demonstrated to be catalyzed by adenosine deaminase acting on RNA (ADAR) enzymes (Kim et al., 1994; O'Connell et al., 1997). Inosine is formed by ADAR-catalyzed hydrolytic deamination of adenosine at the C6 position in dsRNA (Gerber et al., 1997). In the 1990s, a limited number of editing sites were identified in the coding region of mRNA by Sanger sequencing (Sommer et al., 1991). In the last decade, the emergence of next-generation sequencing has enabled the comprehensive identification of 4.5 million editing sites in the noncoding and coding regions of the human transcriptome (Picardi et al., 2017). Since inosine is recognized by the cellular machinery as guanosine, the conversion of nucleotides can affect gene function and expression.

2.1. Molecular basis of adenosine deaminase acting on RNA (ADAR)

In mammals, there are three types of ADARs, ADAR1, ADAR2 (ADARB1), and ADAR3 (ADARB2) (Bass et al., 1997). ADARs have a highly conserved deaminase domain in the C-terminal region and dsRNA-binding domains in the N-terminal region, required for A-to-I RNA editing activity (Nishikura, 2016). ADAR1 has two isoforms, ADAR1 p110 (110 kDa protein) and ADAR1 p150 (150 kDa protein), by using alternative promoters. ADAR1 p110 is constitutively expressed in most human tissues and is localized in the nucleus, whereas ADAR1 p150 expression is induced by interferon and it is localized in both the nucleus and cytoplasm (Patterson and Samuel, 1995; Desterro et al., 2003). ADAR2, which is also a ubiquitous protein, is highly expressed in the brain and is localized in the nucleus (Melcher et al., 1996a). ADAR1 has a 5' neighbor preference (A = U > C > G) but no apparent 3' neighbor preference (Riedmann et al., 2000). ADAR2 has a 5' neighbor preference (A ≈ U > C = G) which is similar to that of ADAR1 and has a 3' neighbor preference (U = G > C = A) (Polson

and Bass, 1994). Homodimerization is required for ADAR1 p110, ADAR1 p150, and ADAR2 to exert their editing activities (Cho et al., 2003; Poulsen et al., 2006; Valente and Nishikura, 2007). ADAR3 is mainly expressed in the brain, but it does not have editing activity (Melcher et al., 1996b; Herbert et al., 1997; Chen et al., 2000). A recent study has shown that ADAR3 may disturb ADAR2 function by acting as a competitive inhibitor (Oakes et al., 2017).

2.2. Functional roles of A-to-I RNA editing in gene regulation

According to a study by Picardi et al. (2017), 73% of A-to-I RNA editing events (3,399,200) occurred in protein coding genes in humans. Among them, 0.2% (6,786), 97% (3,286,779), 0.2% (5,236), and 3% (100,399) of editing sites were located in coding regions, introns, 5'-untranslated regions (UTRs), and 3'-UTRs, respectively. The functional consequences of this nucleotide conversion depend on the region where the editing events occur (Fig. 1). Of 6,786 editing events in the coding region, the conversion of 4,388 sites resulted in changes of the amino acid sequence. Nonsynonymous A-to-I RNA editing has a great impact on protein function, although such editing events infrequently occur (Chen et al., 2013). The majority of A-to-I changes occur in introns and possibly affect splicing by creating or deleting alternative splice sites (Hsiao et al., 2018; Tang et al., 2020). The identified RNA editing sites have been compiled into databases such as DARNED (<https://darned.ucc.ie/>, Kiran et al., 2013) and REDIPortal (<http://srv00.recas.ba.infn.it/atlas/>, Picardi et al., 2017), but the functional significance of most of them remains to be clarified.

In recent years, the presence of circular RNAs, ring-shaped stable noncoding RNAs, which are produced during the “back-splicing” of exons and function as miRNA sponges, has been revealed (Hsiao et al., 2017). It is interesting that the A-to-I editing event in circular RNA precursors inhibits ring formation (Rybak-Wolf et al., 2014; Ivanov et al., 2015). A-to-I editing within the 3'-UTR possibly creates or destroys the binding site of miRNAs (Borchert et al., 2009) and can affect the nuclear retention of mRNA (Hundley and Bass, 2010). In the process of miRNA biogenesis, primary transcripts (pri-miRNAs) are processed into precursor miRNAs (pre-miRNAs) in the nucleus and they are then transported into the cytoplasm to undergo

further processing into mature miRNAs. The stem-loop structures of pri-miRNAs and pre-miRNAs can be targeted by ADARs (Luciano et al., 2004; Kawahara et al., 2007). The editing events in a miRNA transcript can change its processing, influencing miRNA expression. In other cases, A-to-I conversion of the miRNA seed sequence, which is nucleotides 2–7 at the 5'-end of the miRNA and is critical for recognition of the targets (Lewis et al., 2005), could change its target binding efficiency (Alon et al., 2012; Nakano et al., 2017). In addition, it has been reported that ADAR1 promotes the generation of miRNA in an editing-independent manner by interacting with the microprocessor complex (Ota et al., 2013).

2.3. Physiological and pathological roles of A-to-I RNA editing

Early studies showed that A-to-I editing plays key roles in the central nervous system (Tariq and Jantsch, 2012). For example, 5-hydroxytryptamine receptor subtype 2C and glutamate receptor subtype A2 are known to undergo A-to-I RNA editing (Sommer et al., 1991; Lomeli et al., 1994; Burns et al., 1997), and the disruption of RNA editing in these RNAs leads to Prader-Willi syndrome and amyotrophic lateral sclerosis, respectively (Kawahara et al., 2004; Morabito et al., 2010). In addition, aberrant A-to-I RNA editing or ADAR expression is associated with other diseases, including cancer, metabolic diseases, neurological disorders, viral infections, and autoimmune disorders (Song et al., 2016). In particular, it has been elucidated by recent research that ADAR1 is commonly overexpressed in liver, lung, breast, and esophageal cancer as well as in chronic myelogenous leukemia and it promotes cancer progression (Xu and Öhman, 2018). ADAR1-mediated RNA editing contributes to carcinogenesis by reducing the activity of tumor suppressors such as bladder cancer-associated protein or enhancing the activity of oncogenic proteins such as antizyme inhibitor 1 by changing their amino acid sequences (Chen et al., 2013; Hu et al., 2015). Our research group demonstrated that ADAR1 positively regulates the expression of dihydrofolate reductase (DHFR), a key enzyme in folate metabolism, by disrupting the miRNA binding sites in the 3'-UTR of DHFR, enhancing the proliferation of breast cancer cells (Nakano et al., 2017). Therefore, ADAR1 is expected to be a novel target for cancer therapy.

2.4. A-to-I RNA editing modulates drug metabolism potency

In REDiportal, drug metabolism-related genes are registered as mRNAs that are subjected to A-to-I RNA editing (Table 1). Recently, our research group found large (over 200-fold) interindividual variability in ADAR1 expression in human liver samples (Nakano et al., 2016). This finding prompted us to investigate the involvement of ADAR1 in the interindividual differences in hepatic expression of drug-metabolizing enzymes (Nakano and Nakajima, 2018b). Recent findings of A-to-I editing-mediated regulation of drug metabolism-related genes are summarized in Table 1 and introduced below in detail.

2.4.1. ADARs modulate drug-metabolizing P450 expression

To examine the role of ADARs in the regulation of drug-metabolizing P450 expression in the human liver, we knocked down ADAR1 or ADAR2 in HepaRG cells (Nozaki et al., 2019), which show higher P450 expression than HepG2 cells (Guillouzo et al., 2007). Knockdown of ADAR1 or ADAR2 resulted in a decrease to in CYP2C8 mRNA (66% and 54% of control, respectively) and protein expression (77% and 64% of control, respectively) in a promoter region-dependent manner. The CYP2C8-catalyzed amodiaquine *N*-desethylation activity was significantly decreased to 64% and 40% of control by the knockdown of ADAR1 and ADAR2, respectively. We found that the decreased expression of HNF4 α protein (63% and 79% of control, respectively) (but not mRNA) by the knockdown of ADAR1 or ADAR2 was the reason for the decreased transactivity of CYP2C8 (30% and 49% of control, respectively) (Ferguson et al., 2005) (Fig. 2). The mRNA levels of other P450 isoforms, such as CYP2A6, 2C9, 2C19, 2D6, and 2E1, which are known to be regulated by HNF4 α (Kamiyama et al., 2007; Chen et al., 2018), were also reduced to 20–81% of control by ADAR1 or ADAR2 knockdown. Exceptionally, the CYP3A4 mRNA level was increased (3-fold) by ADAR1 knockdown, which could be attributed to the increased CAR and PXR expression, as explained below. Thus, ADARs indirectly regulate P450 expression via modulation of the expression of transcription factors or nuclear receptors. In the following three sections, insights into ADAR-mediated

regulation of AhR, CAR, and PXR, which are important for the transcription of drug-metabolizing enzymes, are introduced.

2.4.2. A-to-I RNA editing downregulates AhR expression by creating a miRNA recognition site

AhR is a ligand-responsive transcription factor that modulates the transcription of xenobiotic-metabolizing enzymes such as CYP1A1, CYP1A2, CYP1B1, UGTs, and glutathione *S*-transferases. In response to ligand binding, AhR forms a heterodimer with aryl hydrocarbon receptor nuclear translocator (Arnt) and it binds to the upstream region of its target genes (Ramados et al., 2005). The 3'-UTR of AhR has an everted Alu repeat, which can form a dsRNA structure, a typical target of ADAR. By Sanger sequence analysis, in which RNA editing sites show a peak of guanosine along with that of adenosine in cDNA but show a single adenosine peak in genomic DNA, we identified 38 ADAR1-mediated A-to-I RNA editing sites in the 3'-UTR of AhR in the human liver. These editing events negatively regulate AhR expression in human hepatoma-derived Huh-7 cells by creating a recognition site of miR-378 in the 3'-UTR of AhR (Nakano et al., 2016) (Fig. 2). The downregulation of AhR attenuated the 2,3,7,8-tetrachlorodibenzo-*p*-dioxin-mediated induction of CYP1A. In human liver samples, there is a significant inverse correlation between the miR-378 and AhR protein levels, suggesting that the RNA editing-dependent downregulation of AhR by miR-378 contributes to the variable expression of AhR in human liver. This is the first evidence to show that A-to-I RNA editing regulates xenobiotic metabolism-related genes.

2.4.3. ADAR1 disrupts splicing of CAR mRNA

CAR is a member of the nuclear receptor superfamily and it is a crucial regulator of drug metabolism and excretion. CAR is activated by some synthetic compounds, drugs, and natural products (Chang and Waxman, 2006) and it induces the expression of CYP2B6, CYP2C9, CYP3A4, UGTs, sulfotransferases, and drug transporters (Negishi and Honkakoski, 2000; Moore et al., 2006). We found that ADAR1 negatively regulates CAR expression in human

hepatoma-derived HepG2 cells, resulting in attenuation of the ligand-dependent induction of CYP2B6 and CYP3A4. As for the mechanism of negative regulation of CAR by ADAR1, it was demonstrated that ADAR1 attenuates the splicing of CAR intron 3, which has two inverted Alu elements but does not have A-to-I RNA editing sites (Nakano et al., 2019) (Fig. 2). ADAR1 may bind to the dsRNA in intron 3 of CAR pre-mRNA, resulting in the attenuation of splicing in an RNA editing activity-independent manner.

2.4.4. ADARs promote degradation of PXR mRNA

PXR is a nuclear receptor that regulates the expression of at least 40 types of genes, including P450s, UGTs, sulfotransferases, glutathione *S*-transferases, and drug transporters (Kliewer et al., 2002). In our recent study, it was found that the knockdown of ADAR1 or ADAR2 significantly increased PXR protein levels (1.5–1.9-fold) in HepaRG and HepG2 cells via attenuation of mRNA degradation, resulting in increased CYP3A4 (71-fold) and UGT1A1 (1.9-fold) expression. A luciferase assay demonstrated that the 3′-UTR of PXR mRNA is responsible for the ADAR-mediated posttranscriptional regulation of PXR expression, despite the lack of RNA edited sites in this region (Takemoto et al., 2021). Although the underlying mechanism of ADAR-mediated downregulation via the 3′-UTR has not been clarified, ADARs may edit the seed sequence of certain miRNAs to create a novel miRNA-PXR mRNA interaction. It has been suggested that the ADAR1-mediated negative regulation of PXR would be a reason for the negative regulation of CYP3A4 by ADAR as described in Section 2.4.1.

2.5. Cigarette smoke induces degradation of ADAR1 protein

Recently, we performed a study to identify extrinsic factors affecting ADAR expression and found that cigarette smoke extract (CSE) treatment decreased ADAR1 protein expression to 45% of control in human lung carcinoma-derived A549 cells (Takizawa et al., 2020). Additionally, exposure to cigarette smoke decreased pulmonary Adar1 protein in mice to 70% of control. The reduction in ADAR1 expression by CSE was demonstrated to be caused by the degradation of ADAR1 protein via the autophagy pathway. Cigarette smoking induces

oxidative stress, which is relevant to the pathophysiology of chronic obstructive pulmonary disease (Ahmad et al., 2013). Interestingly, we also demonstrated that the knockdown of ADAR1 resulted in an increase (1.3-fold) in CSE-induced oxidative stress and a decrease in superoxide dismutase activity (88% of control) and heme oxygenase-1 expression (32% of control), indicating that ADAR1 has a role in suppressing oxidative stress. Thus, it was demonstrated that ADAR1 has a role in regulating the biological response to protect against xenobiotic exposure.

3. m⁶A modification

In addition to A-to-I RNA editing, RNA is subjected to nearly 160 kinds of modifications, such as methylation of adenosine at the N⁶ position (m⁶A modification), methylation of adenosine at the N¹ position (m¹A modification), dimethylation of adenosine at the N⁶ and ribose 2'-O positions (m⁶Am modification), methylation of cytidine at the C⁵ position (m⁵C modification), and hydroxylation of m⁵C (hm⁵C modification), which do not result in nucleotide conversion. Among them, m⁶A modification is the most prevalent internal chemical modification of mRNA, which was discovered more than 45 years ago in the rat, mouse, and human transcriptomes (Desrosiers et al., 1974; Adams and Cory, 1975; Furuichi et al., 1975). Due to the lack of a methodology for the site-specific detection of m⁶A, the cellular function of m⁶A modification has been unclear over the years (Dominissini et al., 2012). Next generation sequencing techniques combined with RNA immunoprecipitation using an anti-m⁶A antibody revealed that m⁶A ubiquitously occurred in the DRACH (D = A, G or U; R = A or G; H = A, C or U) motif mainly located near the stop codon in the last exon and was secondarily located in the 5'-UTR (Dominissini et al., 2012; Meyer et al., 2012), and 480,000 m⁶A sites were identified in the human transcriptome (Xuan et al., 2018). Elucidation of the physiological significance of m⁶A modification has just started.

3.1. m⁶A writers and erasers

m⁶A is deposited by a methyltransferase complex containing methyltransferase-like 3

(METTL3) and METTL14, which are called “m⁶A writers” (Liu et al., 2014; Ping et al., 2014; Schwartz et al., 2014). METTL3 is catalytically active, whereas METTL14 is an allosteric activator (Śledź and Jinek, 2016; Wang et al., 2016). This METTL3-METTL14 complex catalyzes the majority of m⁶A modifications on mRNA (Geula et al., 2015). In this reaction, *S*-adenosylmethionine (SAM) is used as a methyl donor. Additionally, METTL16 has been found to possess potential m⁶A methyltransferase activity (Warda et al., 2017).

m⁶A is reversibly demethylated to adenosine by the “m⁶A eraser”. The first identified m⁶A eraser was fat mass and obesity-associated (FTO) (Jia et al., 2011). FTO is a member of the Fe(II)- and α -ketoglutarate-dependent AlkB family (Gerken et al., 2007), and its loss results in reduced body weight and food intake in mice (Fischer et al., 2009; Church et al., 2010). FTO-catalyzed demethylation of m⁶A involves stepwise oxidation of m⁶A to *N*⁶-hydroxymethyladenosine and *N*⁶-formyladenosine to adenosine (Fu et al., 2013). FTO is also known to preferentially demethylate m⁶Am in the 5' cap of mRNA (Mauer et al., 2017). AlkB homolog 5 (ALKBH5), the second identified m⁶A eraser, is also a member of the Fe(II) and α -ketoglutarate-dependent AlkB family. Unlike FTO, ALKBH5 directly demethylates m⁶A to adenosine (Zheng, John Arne Dahl, et al., 2013) since the intermediate is unlikely to be detected in the process of demethylation. Thus, m⁶A is dynamically and reversibly regulated by “m⁶A writers” and “m⁶A erasers” (Fig. 3).

3.2. Functional roles of m⁶A modification in gene regulation

Unlike A-to-I RNA editing, m⁶A modification does not result in base conversion but instead exerts its functions by recruiting proteins called “m⁶A readers”. The first identified readers were YTH (YT521-B homology) domain-containing proteins (Dominissini et al., 2012). In humans, there are five members, YTHDF1, YTHDF2, YTHDF3, YTHDC1, and YTHDC2. YTHDF1 delivers m⁶A-containing mRNA to the translation machinery and enhances translation initiation (Wang et al., 2015). YTHDF2 enhances the degradation of m⁶A-modified mRNA by deadenylation and translocation into the P-body (Wang et al., 2014; Du et al., 2016). YTHDF3 promotes the translation of targeted mRNAs by interacting with

YTHDF1 (Shi et al., 2017). YTHDC1 mediates splicing (Xiao et al., 2016) and nuclear export of m⁶A-modified mRNA (Roundtree et al., 2017). YTHDC2 promotes the translation efficiency of its target m⁶A-containing mRNAs and promote mRNA degradation (Hsu et al., 2017; Kretschmer et al., 2018). Thus, various steps of mRNA processing are potentially affected by the binding of readers to m⁶A.

m⁶A modification can affect miRNA processing (Fig. 3). m⁶A modification of pri-miRNAs recruits heterogeneous nuclear ribonucleoprotein A2/B1, which interacts with DGCR8 of pri-let-7e to facilitate miRNA biogenesis (Alarcón et al., 2015). Another example is that NF-κB-activating protein recognizes m⁶A in pri-miR-25 to recruit DGCR8, resulting in maturation promotion (Zhang et al., 2019). Since knowledge about the functional roles of m⁶A modification of miRNA precursors is limited, additional studies are needed for a comprehensive understanding of the roles of m⁶A modification in miRNA maturation.

3.3. Physiological and pathological roles of m⁶A modification

Recently, accumulating evidence suggests that m⁶A modification plays significant roles in biological processes such as cell differentiation (Batista et al., 2014), development (Heck and Wilusz, 2019), immune response (O’Connell et al., 2015), and circadian rhythms (Fustin et al., 2013). Thus, disruption of m⁶A levels and dysregulation of m⁶A writers, erasers, and readers are associated with various diseases, such as obesity (Jia et al., 2011), neuronal disorders (Maity and Das, 2016), infectious diseases (Gokhale et al., 2016), cancer (Deng et al., 2018), and infertility (Zheng, et al., 2013). Regarding the physiological role of m⁶A modification in the liver, it has been reported that METTL3 decreases hepatic insulin sensitivity by upregulating fatty acid synthase (Xie et al., 2019) and it enhances lipid accumulation by downregulating peroxisome proliferator-activator α (PPARα) expression (Zhong et al., 2018). Hepatic METTL3 expression in type 2 diabetes mellitus patients is higher than that in healthy subjects (Xie et al., 2019). Thus, m⁶A modification plays important roles in hepatic lipid metabolism.

3.4. m⁶A modification modulates drug metabolism potency

In RMBase (<https://rna.sysu.edu.cn/rmbase/index.php>), a database of RNA modification, drug metabolism-related genes are registered as mRNAs that are subjected to m⁶A modification (Table 2). Our group has revealed that the m⁶A modification actually has significance in the regulation of drug metabolism. In the following sections, our recent findings that m⁶A modification regulates P450, UGT, and esterase isoforms are summarized in Table 2 and introduced in detail.

3.4.1. m⁶A modification downregulates CYP2C8 expression

To examine whether m⁶A modification affects P450 expression, we evaluated the expression levels of P450 isoforms in HepaRG cells treated with 3-deazaadenosine (DAA), an inhibitor of SAM synthesis (Chiang, 1998; Nakano et al., 2020). CYP1A2 (1.6-fold), 2B6 (2.2-fold), and 2C8 (2.7-fold) expression levels were significantly increased by treatment with DAA. The CYP2C8 expression level and enzymatic activity were increased (1.4–2.0-fold) by silencing of METTL3 and METTL14, but it was reduced to 22–75% of control by silencing of FTO but not by ALKBH5. By immunoprecipitation of m⁶A-containing RNA using an anti-m⁶A antibody, we found that the 5'-UTR and the 3'-UTR of CYP2C8 mRNA undergo m⁶A modification in HepaRG cells and human liver samples. The m⁶A modification in the 3'-UTR of CYP2C8 negatively regulates CYP2C8 expression by recruiting YTHDC2, which promotes the degradation of CYP2C8 mRNA (Fig. 4). This is the first study to demonstrate m⁶A modification-mediated regulation of P450 isoforms.

3.4.2. m⁶A modification downregulates UGT2B7 expression

To expand the knowledge of m⁶A modification-mediated regulation of drug metabolism potencies, we investigated whether m⁶A modification regulates UGT isoforms (Ondo et al., 2021). Treatment of HepaRG cells with DAA significantly increased (1.3–2.6-fold) the UGT1A1, 1A3, 1A4, 1A9, 2B7, 2B10, and 2B15 mRNA levels. Among them, we focused on UGT2B7 because it most highly contributes to glucuronidation of clinically used drugs

(Williams et al., 2004). The UGT2B7 expression level in Huh-7 cells was significantly increased (1.5-fold) by double knockdown of METTL3 and METTL14 but was reduced to 70% and 66% of control by knockdown of FTO or ALKBH5, respectively, suggesting that m⁶A modification negatively regulates UGT2B7 expression. Methylated RNA immunoprecipitation assays revealed that the 5'-UTR and the 3'-UTR of UGT2B7 mRNA have m⁶A modification sites in HepaRG cells and human livers. However, these methylation events do not directly affect the UGT2B7 expression level. Reporter assays demonstrated that the promoter region has a key role in m⁶A modification-mediated regulation of UGT2B7. We found that the expression level of HNF4 α , which regulates the transcription of UGT2B7, was significantly reduced to 46% of control by knockdown of FTO, indicating that this would be the underlying mechanism of m⁶A modification-mediated negative regulation of UGT2B7 transactivation. Since HNF4 α also transactivates *CYP2C8* (Ferguson et al., 2005), the negative regulation of HNF4 α by m⁶A modification contributes to the downregulation of *CYP2C8* expression by the m⁶A modification described above. Further study is needed to clarify the effects of m⁶A modification-mediated repression of HNF4 α expression on the other P450 and UGT isoforms. Entacapone, which is used for treating Parkinson's disease, has been reported to inhibit FTO *in vitro* and *in vivo* (Peng et al., 2019). Interestingly, treatment with entacapone decreased HNF4 α and UGT2B7 expression to 35% and 21%, respectively. Thus, entacapone has the potential to cause drug-drug interactions through the negative regulation of UGT2B7 (Fig. 4). This study provided novel insight into a unique regulatory mechanism for UGT expression.

3.4.3. m⁶A modification downregulates CES2 expression

Carboxylesterase 2 (CES2) is a serine esterase responsible for the hydrolysis of various drugs, such as 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11), and endogenous substrates, such as triglycerides and diacylglycerides (Humerickhouse et al., 2000; Ruby et al., 2017). Recently, we revealed that m⁶A modification affects drug and lipid metabolism by regulating hepatic CES2 expression (Takemoto et al., 2021) (Fig. 4). The CES2 expression level and its hydrolase activity for CPT-11 in HepaRG and HepG2 cells were

significantly increased (1.2–1.4-fold) by double knockdown of METTL3 and METTL14 but were reduced to 25–81% of control by knockdown of FTO or ALKBH5, suggesting that m⁶A modification downregulates CES2 expression. Consistently, cellular lipid accumulation was decreased to 82% of control by double knockdown of METTL3 and METTL14, but it was increased (1.2–1.5-fold) by knockdown of FTO or ALKBH5. RNA immunoprecipitation assays using an anti-m⁶A antibody revealed that the 5'-UTR and the last exon of CES2 are subjected to m⁶A modification. We found that YTHDC2 recognizes m⁶A in the 5'-UTR of CES2 and promotes the degradation of CES2 mRNA. Because CES2 is also transcriptionally regulated by HNF4 α (Li et al., 2016), m⁶A may indirectly contribute to the downregulation of CES2 via attenuation of HNF4 α expression. Collectively, m⁶A modification has a strong impact on the regulation of CES2, affecting pharmacokinetics, drug responses and lipid metabolism.

4. Conclusion

In this review article, current knowledge about A-to-I RNA editing and m⁶A modification-dependent regulation of drug metabolism is summarized. The significance of such posttranscriptional regulation in the field of pharmacokinetics research has only recently started to become clear. In addition to drug-metabolizing enzymes, some drug transporters have been reported to be subjected to posttranscriptional regulation. Omata et al. (2021) reported that ADAR1 regulates P-glycoprotein in human renal cells by affecting its alternative splicing. Xiao et al. (2021) reported that FTO upregulates multidrug resistance-associated protein 7 expression in non-small cell lung cancer to confer gefitinib resistance. Thus, A-to-I RNA editing and m⁶A modifications could be distinct regulators of pharmacokinetics.

In addition to the regulation of drug-metabolizing enzymes and transporters, A-to-I RNA editing and m⁶A modification have been shown to impact the sensitivity of anticancer drugs. Ishizuka et al. (2019) reported, by using syngeneic mouse models, that knockout of *Adar1* sensitizes tumors to immune checkpoint blockade. Sun et al. (2020) reported that ADAR1 contributes to resistance to bromodomain and extraterminal domain inhibitors in pancreatic cancer cells. Thus, inhibition of ADAR1 would be a promising approach to overcome cancer resistance. There are currently no clinically used ADAR inhibitors, although adenosine analogs, 8-azaadenosine and 8-chloroadenosine, have been reported to inhibit ADAR1 (Zipeto et al., 2016; Ding et al., 2020; Ramírez-Moya et al., 2020). These compounds would be useful, but a recent study reported that they are not selective inhibitors of ADAR1 (Cottrell et al., 2021). Thus, the development of novel specific inhibitors of ADAR1 is desired. Knowledge about the roles of m⁶A modification in the cancer therapy response is more mature than knowledge about A-to-I editing and it has been recently summarized in a review by Lan et al. (2021). For example, FTO expression levels are increased during the development of resistance to tyrosine kinase inhibitors, and rhein, an inhibitor of FTO, restores sensitivity to tyrosine kinase inhibitors (Yan et al., 2018). m⁶A modification would also be an attractive target for cancer therapy. In addition to cancer, knowledge about significance of FTO in energy metabolism has been accumulated. Research using mouse models have shown that ubiquitous

overexpression and knockout of *Fto* results in obesity and reduced body weight, respectively (Fischer et al., 2009; Church et al., 2010). Because HNF4 α and CES2 are known to regulate lipid and glucose metabolisms (Gonzalez, 2008; Ruby et al., 2017), FTO-mediated upregulation of HNF4 α and CES2 (described in Sections 2.4.1 and 2.4.2) would be a piece of the functional roles of FTO in energy metabolism. Inhibition of FTO using entacapone and rhein would be a promising strategy for treatment of metabolic disorders such as obesity and diabetes.

Until now, the roles of A-to-I RNA editing and m⁶A modification in the regulation of drug metabolism-related genes have been examined separately. It has been reported that A-to-I editing preferentially occurs in m⁶A-negative transcripts, indicating that these posttranscriptional regulations may suppressively interfere with each other (Xiang et al., 2018). As described above, A-to-I RNA editing positively regulates CYP2C8 expression (Fig. 2), whereas m⁶A modification negatively regulates CYP2C8 expression (Fig. 4). There is a possibility that A-to-I RNA editing upregulates CYP2C8 expression by repressing m⁶A modification-mediated negative regulation, and *vice versa*. To deeply understand the importance of these two posttranscriptional regulations in the regulation of drug-metabolizing enzymes, it should be noted that one posttranscriptional modification affects the levels of the other modification on the same transcript.

It is now clear that A-to-I RNA editing and m⁶A modification are novel regulators of drug metabolism potency. Elucidation of the extent and causes of inter- and intraindividual differences in these posttranscriptional modifications as well as the development of inhibitors and activators for RNA modifications are expected to contribute to the practice of personalized medicine.

Authorship contributions

Wrote or contributed to the writing of the manuscript: Nakano M and Nakajima M

References

- Adams JM and Cory S (1975) Modified nucleosides and bizarre 5'-termini in mouse myeloma mRNA. *Nature* **255**: 28–33.
- Ahmad A, Shameem M, and Husain Q (2013) Altered oxidant-antioxidant levels in the disease prognosis of chronic obstructive pulmonary disease. *Int J Tuberc Lung Dis* **17**: 1104–1109.
- Alarcón CR, Lee H, Goodarzi H, Halberg N, and Tavazoie SF (2015) N6-methyladenosine marks primary microRNAs for processing. *Nature* **519**: 482–485.
- Alon S, Mor E, Vigneault F, Church GM, Locatelli F, Galeano F, Gallo A, Shomron N, and Eisenberg E (2012) Systematic identification of edited microRNAs in the human brain. *Genome Res* **22**: 1533–1540.
- Bass BL, Nishikura K, Keller W, Seeburg PH, Emeson RB, O'Connell MA, Samuel CE, and Herbert A (1997) A standardized nomenclature for adenosine deaminases that act on RNA. *RNA* **3**: 947–949.
- Bass BL and Weintraub H (1987) A developmentally regulated activity that unwinds RNA duplexes. *Cell* **48**: 607–613.
- Bass BL and Weintraub H (1988) An unwinding activity that covalently modifies its double-stranded RNA substrate. *Cell* **55**: 1089–1098.
- Batista PJ, Molinie B, Wang J, Qu K, Zhang J, Li L, Bouley DM, Lujan E, Haddad B, Daneshvar K, Carter AC, Flynn RA, Zhou C, Lim K-S, Dedon P, Wernig M, Mullen AC, Xing Y, Giallourakis CC, and Chang HY (2014) m6A RNA modification controls cell fate transition in mammalian embryonic stem cells. *Cell Stem Cell* **15**: 707–719.
- Boccaletto P, Machnicka MA, Purta E, Piątkowski P, Bagiński B, Wirecki TK, de Crécy-Lagard V, Ross R, Limbach PA, Kotter A, Helm M, and Bujnicki JM (2018) MODOMICS: a database of RNA modification pathways. 2017 update. *Nucleic Acids Res* **46**: D303–D307.
- Borchert GM, Gilmore BI, Spengler RM, Xing Y, Lanier W, Bhattacharya D, and Davidson BL (2009) Adenosine deamination in human transcripts generates novel microRNA binding

- sites. *Hum Mol Genet* **18**: 4801–4807.
- Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E, and Emeson RB (1997) Regulation of serotonin-2C receptor G-protein coupling by RNA editing. *Nature* **387**: 303–308.
- Chang TKH and Waxman DJ (2006) Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). *Drug Metab Rev* **38**: 51–73.
- Chen CX, Cho DSC, Wang Q, Lai F, Carter KC, and Nishikura K (2000) A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains. *RNA* **6**: 755–767.
- Chen L, Bao Y, Piekos SC, Zhu K, Zhang L, and Zhong XB (2018) A transcriptional regulatory network containing nuclear receptors and long noncoding RNAs controls basal and drug-induced expression of cytochrome P450s in HepaRG cells. *Mol Pharmacol* **94**: 749–759.
- Chen L, Li Y, Lin CH, Chan THM, Chow RKK, Song Y, Liu M, Yuan YF, Fu L, Kong KL, Qi L, Li Y, Zhang N, Tong AHY, Kwong DLW, Man K, Lo CM, Lok S, Tenen DG, and Guan XY (2013) Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. *Nat Med* **19**: 209–216.
- Chiang PK (1998) Biological effects of inhibitors of S-adenosylhomocysteine hydrolase. *Pharmacol Ther* **77**: 115–134.
- Cho DSC, Yang W, Lee JT, Shiekhataar R, Murray JM, and Nishikura K (2003) Requirement of dimerization for RNA editing activity of adenosine deaminases acting on RNA. *J Biol Chem* **278**: 17093–17102.
- Church C, Moir L, McMurray F, Girard C, Banks GT, Teboul L, Wells S, Brüning JC, Nolan PM, Ashcroft FM, and Cox RD (2010) Overexpression of Fto leads to increased food intake and results in obesity. *Nat Genet* **42**: 1086–1092.
- Cottrell KA, Soto Torres L, and Weber JD (2021) 8-Azaadenosine and 8-chloroadenosine are not selective inhibitors of ADAR. *bioRxiv* 2021.05.12.443853.

- Deng X, Su R, Feng X, Wei M, and Chen J (2018) Role of N6-methyladenosine modification in cancer. *Curr Opin Genet Dev* **48**: 1–7.
- Desrosiers R, Friderici K, and Rottman F (1974) Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. *Proc Natl Acad Sci USA* **71**: 3971–3975.
- Desterro JMP, Keegan LP, Lafarga M, Berciano MT, O’Connell M, and Carmo-Fonseca M (2003) Dynamic association of RNA-editing enzymes with the nucleolus. *J Cell Sci* **116**: 1805–1818.
- Ding HY, Yang WY, Zhang LH, Li L, Xie F, Li HY, Chen XY, Tu Z, Li Y, Chen Y, and Yang SY (2020) 8-Chloro-Adenosine Inhibits Proliferation of MDA-MB-231 and SK-BR-3 Breast Cancer Cells by Regulating ADAR1/p53 Signaling Pathway. *Cell Transplant* **29**: 963689720958656.
- Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, Cesarkas K, Jacob-Hirsch J, Amariglio N, Kupiec M, Sorek R, and Rechavi G (2012) Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. *Nature* **485**: 201–206.
- Du H, Zhao Y, He J, Zhang Y, Xi H, Liu M, Ma J, and Wu L (2016) YTHDF2 destabilizes m6A-containing RNA through direct recruitment of the CCR4-NOT deadenylase complex. *Nat Commun* **7**: 1–11.
- Ferguson SS, Chen Y, LeCluyse EL, Negishi M, and Goldstein JA (2005) Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4a. *Mol Pharmacol* **68**: 747–757.
- Fischer J, Koch L, Emmerling C, Vierkotten J, Peters T, Brüning JC, and Rüther U (2009) Inactivation of the Fto gene protects from obesity. *Nature* **458**: 894–898.
- Fu Y, Dominissini D, Rechavi G, and He C (2014) Gene expression regulation mediated through reversible m6A RNA methylation. *Nat Rev Genet* **15**: 293–306.
- Fu Y, Jia G, Pang X, Wang RN, Wang X, Li CJ, Smemo S, Dai Q, Bailey KA, Nobrega MA, Han KL, Cui Q, and He C (2013) FTO-mediated formation of

- N6-hydroxymethyladenosine and N 6-formyladenosine in mammalian RNA. *Nat Commun* **4**: 1–8.
- Furuichi Y, Morgan M, Shatkin AJ, Jelinek W, Salditt-Georgieff M, and Darnell JE (1975) Methylated, blocked 5' termini in HeLa cell mRNA. *Proc Natl Acad Sci USA* **72**: 1904–1908.
- Fustin JM, Doi M, Yamaguchi Y, Hida H, Nishimura S, Yoshida M, Isagawa T, Morioka MS, Kakeya H, Manabe I, and Okamura H (2013) RNA-methylation-dependent RNA processing controls the speed of the circadian clock. *Cell* **155**: 793–806.
- Gerber A, O'Connell MA, and Keller W (1997) Two forms of human double-stranded RNA-specific editase 1 (hRED1) generated by the insertion of an Alu cassette. *RNA* **3**: 453–463.
- Gerken T, Girard CA, Tung YCL, Webby CJ, Saudek V, Hewitson KS, Yeo GSH, McDonough MA, Cunliffe S, McNeill LA, Galvanovskis J, Rorsman P, Robins P, Prieur X, Coll AP, Ma M, Jovanovic Z, Farooqi IS, Sedgwick B, Barroso I, Lindahl T, Ponting CP, Ashcroft FM, O'Rahilly S, and Schofield CJ (2007) The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. *Science* **318**: 1469–1472.
- Geula S, Moshitch-Moshkovitz S, Dominissini D, Mansour AAF, Kol N, Salmon-Divon M, Hershkovitz V, Peer E, Mor N, Manor YS, Ben-Haim MS, Eyal E, Yunger S, Pinto Y, Jaitin DA, Viukov S, Rais Y, Krupalnik V, Chomsky E, Zerbib M, Maza I, Rechavi Y, Massarwa R, Hanna S, Amit I, Levanon EY, Amariglio N, Stern-Ginossar N, Novershtern N, Rechavi G, and Hanna JH (2015) m6A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation. *Science* **347**: 1002–1006.
- Gokhale NS, McIntyre ABR, McFadden MJ, Roder AE, Kennedy EM, Gandara JA, Hopcraft SE, Quicke KM, Vazquez C, Willer J, Ilkayeva OR, Law BA, Holley CL, Garcia-Blanco MA, Evans MJ, Suthar MS, Bradrick SS, Mason CE, and Horner SM (2016) N6-methyladenosine in flaviviridae viral RNA genomes regulates infection. *Cell Host Microbe* **20**: 654–665.
- Gonzalez FJ (2008) Regulation of Hepatocyte Nuclear Factor 4 α -mediated Transcription. *Drug*

Metab Pharmacokinet **23**: 2–7.

- Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C (2007) The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. *Chem Biol Interact* **20**: 66–73.
- Heck AM, and Wilusz CJ (2019) Small changes, big implications: The impact of m6A RNA methylation on gene expression in pluripotency and development. *Biochim Biophys Acta Gene Regul Mech* **1862**: 194402.
- Herbert A, Alfken J, Kim YG, Mian IS, Nishikura K, and Rich A (1997) A Z-DNA binding domain present in the human editing enzyme, double-stranded RNA adenosine deaminase. *Proc Natl Acad Sci USA* **94**: 8421–8426.
- Hsiao KY, Sun HS, and Tsai SJ (2017) Circular RNA – New member of noncoding RNA with novel functions. *Exp Biol Med* **242**: 1136–1141.
- Hsiao YHE, Bahn JH, Yang Y, Lin X, Tran S, Yang EW, Quinones-Valdez G, and Xiao X (2018) RNA editing in nascent RNA affects pre-mRNA splicing. *Genome Res* **28**: 812–823.
- Hsu PJ, Zhu Y, Ma H, Guo Y, Shi X, Liu Y, Qi M, Lu Z, Shi H, Wang J, Cheng Y, Luo G, Dai Q, Liu M, Guo X, Sha J, Shen B, and He C (2017) Ythdc2 is an N6 -methyladenosine binding protein that regulates mammalian spermatogenesis. *Cell Res* **27**: 1115–1127.
- Hu X, Wan S, Ou Y, Zhou B, Zhu J, Yi X, Guan Y, Jia W, Liu X, Wang Q, Qi Y, Yuan Q, Huang W, Liao W, Wang Y, Zhang Q, Xiao H, Chen X, and Huang J (2015) RNA over-editing of BLCAP contributes to hepatocarcinogenesis identified by whole-genome and transcriptome sequencing. *Cancer Lett* **357**: 510–519.
- Humerickhouse R, Lohrbach K, Li L, Bosron WF, and Dolan ME (2000) Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. *Cancer Res* **60**: 1189–1192.
- Hundley HA and Bass BL (2010) ADAR editing in double-stranded UTRs and other noncoding RNA sequences. *Trends Biochem Sci* **35**: 377–383.
- Ishizuka JJ, Manguso RT, Cheruiyot CK, Bi K, Panda A, Iracheta-Vellve A, Miller BC, Du PP,

- Yates KB, Dubrot J, Buchumenski I, Comstock DE, Brown FD, Ayer A, Kohnle IC, Pope HW, Zimmer MD, Sen DR, Lane-Reticker SK, Robitschek EJ, Griffin GK, Collins NB, Long AH, Doench JG, Kozono D, Levanon EY, and Haining WN (2019) Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. *Nature* **565**: 43–48.
- Ivanov A, Memczak S, Wyler E, Torti F, Porath HT, Orejuela MR, Piechotta M, Levanon EY, Landthaler M, Dieterich C, and Rajewsky N (2015) Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals. *Cell Rep* **10**: 170–177.
- Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, Yi C, Lindahl T, Pan T, Yang YG, and He C (2011) N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. *Nat Chem Biol* **7**: 885–887.
- Kamiyama Y, Matsubara T, Yoshinari K, Nagata K, Kamimura H, and Yamazoe Y (2007) Role of human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA. *Drug Metab Pharmacokinet* **22**: 287–298.
- Kawahara Y, Ito K, Sun H, Aizawa H, Kanazawa I, and Kwak S (2004) RNA editing and death of motor neurons. *Nature* **427**: 801.
- Kawahara Y, Zinshteyn B, Chendrimada TP, Shiekhattar R, and Nishikura K (2007) RNA editing of the microRNA-151 precursor blocks cleavage by the Dicer - TRBP complex. *EMBO Rep* **8**: 763–769.
- Kim U, Wang Y, Sanford T, Zeng Y, and Nishikura K (1994) Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing. *Proc Natl Acad Sci USA* **91**: 11457–11461.
- Kiran AM, O'Mahony JJ, Sanjeev K, and Baranov PV (2013) Darned in 2013: inclusion of model organisms and linking with Wikipedia. *Nucleic Acids Res* **41**: D258–D261.
- Kliwer SA, Goodwin B, and Willson TM (2002) The nuclear pregnane X receptor: A key regulator of xenobiotic metabolism. *Endocr Rev* **23**: 687–702.
- Kretschmer J, Rao H, Hackert P, Sloan KE, Höbartner C, and Bohnsack MT (2018) The m6A reader protein YTHDC2 interacts with the small ribosomal subunit and the 5'-3'

- exoribonuclease XRN1. *RNA* **24**: 1339–1350.
- Lan Q, Liu PY, Bell JL, Wang JY, Hüttelmaier S, Zhang XD, Zhang L, and Liu T (2021) The emerging roles of RNA m6A methylation and demethylation as critical regulators of tumorigenesis, drug sensitivity, and resistance. *Cancer Res* **81**: 3431–3440.
- Lewis BP, Burge CB, and Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* **120**: 15–20.
- Li D, Tolleson WH, Yu D, Chen S, Guo L, Xiao W, Tong W, and Ning B (2019) Regulation of cytochrome P450 expression by microRNAs and long noncoding RNAs: Epigenetic mechanisms in environmental toxicology and carcinogenesis. *J Environ Sci Heal Part C* **37**: 1–35.
- Li Y, Zalzal M, Jadhav K, Xu Y, Kasumov T, Yin L, and Zhang Y (2016) Carboxylesterase 2 prevents liver steatosis by modulating lipolysis, endoplasmic reticulum stress, and lipogenesis and is regulated by hepatocyte nuclear factor 4 alpha in mice. *Hepatology* **63**: 1860–1874.
- Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, Jia G, Yu M, Lu Z, Deng X, Dai Q, Chen W, and He C (2014) A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. *Nat Chem Biol* **10**: 93–95.
- Lomeli H, Mosbacher J, Melcher T, Hoyer T, Geiger, Kuner T, Monyer H, Higuchi M, Bach A, and Seeburg P (1994) Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. *Science* **266**: 1709–1713.
- Luciano DJ, Mirsky H, Vendetti NJ, and Maas S (2004) RNA editing of a miRNA precursor. *RNA* **10**: 1174–1177.
- Maity A and Das B (2016) N 6-methyladenosine modification in mRNA : machinery, function and implications for health and diseases. *FEBS J* **283**: 1607–1630.
- Melcher T, Maas S, Herb A, Sprengel R, Higuchi M, and Seeburg PH (1996) RED2, a brain-specific member of the RNA-specific adenosine deaminase family. *J Biol Chem* **271**: 31795–31798.

- Melcher T, Maas S, Herb A, Sprengel R, Seeburg PH, and Higuchi M (1996) A mammalian RNA editing enzyme. *Nature* **379**: 460–464.
- Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, and Jaffrey SR (2012) Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons. *Cell* **149**: 1635–1646.
- Moore DD, Kato S, Xie W, Mangelsdorf DJ, Schmidt DR, Xiao R, and Kliewer SA (2006) International union of pharmacology. LXII. The NR1H and NR1I receptors: Constitutive androstane receptor, pregnane X receptor, farnesoid X receptor α , farnesoid X receptor β , liver X receptor α , liver X receptor β , and vitamin D receptor. *Pharmacol Rev* **58**: 742–59.
- Morabito MV, Abbas AI, Hood JL, Kesterson RA, Jacobs MM, Kump DS, Hachey DL, Roth BL, and Emeson RB (2010) Mice with altered serotonin 2C receptor RNA editing display characteristics of Prader–Willi syndrome. *Neurobiol Dis* **39**: 169–180.
- Nakano M, Fukami T, Gotoh S, and Nakajima M (2017) A-to-I RNA editing up-regulates human dihydrofolate reductase in breast cancer. *J Biol Chem* **292**: 4873–4884.
- Nakano M, Fukami T, Gotoh S, Takamiya M, Aoki Y, and Nakajima M (2016) RNA editing modulates human hepatic aryl hydrocarbon receptor expression by creating MicroRNA recognition sequence. *J Biol Chem* **291**: 894–903.
- Nakano M, Fukami T, and Nakajima M (2019) Adenosine deaminases acting on RNA downregulate the expression of constitutive androstane receptor in the human liver-derived cells by attenuating splicing. *J Pharmacol Exp Ther* **370**: 408–415.
- Nakano M and Nakajima M (2018a) Current knowledge of microRNA-mediated regulation of drug metabolism in humans. *Expert Opin Drug Metab Toxicol* **14**: 493–504.
- Nakano M and Nakajima M (2018b) Significance of A-to-I RNA editing of transcripts modulating pharmacokinetics and pharmacodynamics. *Pharmacol Ther* **181**: 13–21.
- Nakano M, Ondo K, Takemoto S, Fukami T, and Nakajima M (2020) Methylation of adenosine at the N^6 position post-transcriptionally regulates hepatic P450s expression. *Biochem Pharmacol* **171**: 113697.
- Negishi M and Honkakoski P (2000) Induction of drug metabolism by nuclear receptor CAR:

- Molecular mechanisms and implications for drug research. *Eur J Pharm Sci* **11**: 259–264.
- Nishikura K (2016) A-to-I editing of coding and non-coding RNAs by ADARs. *Nat Rev Mol Cell Biol* **17**: 83–96.
- Nozaki K, Nakano M, Iwakami C, Fukami T, and Nakajima M (2019) RNA editing enzymes modulate the expression of hepatic CYP2B6, CYP2C8, and other cytochrome P450 isoforms. *Drug Metab Dispos* **47**: 639–647.
- O’Connell MA, Gerber A, and Keller W (1997) Purification of human double-stranded RNA-specific editase 1 (hRED1) involved in editing of brain glutamate receptor B pre-mRNA. *J Biol Chem* **272**: 473–478.
- O’Connell MA, Mannion NM, and Keegan LP (2015) The epitranscriptome and innate immunity. *PLOS Genet* **11**: e1005687.
- Oakes E, Anderson A, Cohen-Gadol A, and Hundley HA (2017) Adenosine deaminase that acts on RNA 3 (adar3) binding to glutamate receptor subunit B Pre-mRNA Inhibits RNA editing in glioblastoma. *J Biol Chem* **292**: 4326–4335.
- Omata Y, Yamauchi T, Tsuruta A, Matsunaga N, Koyanagi S, and Ohdo S (2021) RNA editing enzyme ADAR1 governs the circadian expression of P-glycoprotein in human renal cells by regulating alternative splicing of the ABCB1 gene. *J Biol Chem* **296**: 100601.
- Ondo K, Isono M, Nakano M, Hashiba S, Fukami T, and Nakajima M (2021) The *N*⁶-methyladenosine modification posttranscriptionally regulates hepatic UGT2B7 expression. *Biochem Pharmacol* **189**: 114402.
- Ota H, Sakurai M, Gupta R, Valente L, Wulff BE, Ariyoshi K, Iizasa H, Davuluri RV, and Nishikura K (2013) ADAR1 forms a complex with dicer to promote MicroRNA processing and RNA-induced gene silencing. *Cell* **153**: 575–589.
- Patterson JB and Samuel CE (1995) Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. *Mol Cell Biol* **15**: 5376–5388.
- Peng S, Xiao W, Ju D, Sun B, Hou N, Liu Q, Wang Yanli, Zhao H, Gao C, Zhang S, Cao R, Li P, Huang H, Ma Y, Wang Yankai, Lai W, Ma Z, Zhang W, Huang S, Wang H, Zhang Z,

- Zhao L, Cai T, Zhao YL, Wang F, Nie Y, Zhi G, Yang YG, Zhang EE, and Huang N (2019) Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1. *Sci Transl Med* **11**: 7116.
- Picardi E, D’Erchia AM, Giudice CL, and Pesole G (2017) REDiportal: A comprehensive database of A-to-I RNA editing events in humans. *Nucleic Acids Res* **45**: D750–D757.
- Ping XL, Sun BF, Wang L, Xiao W, Yang X, Wang WJ, Adhikari S, Shi Y, Lv Y, Chen YS, Zhao X, Li A, Yang Y, Dahal U, Lou XM, Liu X, Huang J, Yuan WP, Zhu XF, Cheng T, Zhao YL, Wang X, Danielsen JMR, Liu F, and Yang YG (2014) Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. *Cell Res* **24**: 177–189.
- Polson AG and Bass BL (1994) Preferential selection of adenosines for modification by double-stranded RNA adenosine deaminase. *EMBO J* **13**: 5701–5711.
- Poulsen H, Jorgensen R, Heding A, Nielsen FC, Bonven B, and Egebjerg J (2006) Dimerization of ADAR2 is mediated by the double-stranded RNA binding domain. *RNA* **12**: 1350–1360.
- Ramadoss P, Marcus C, and Perdew GH (2005) Role of the aryl hydrocarbon receptor in drug metabolism.
- Ramírez-Moya J, Baker AR, Slack FJ, and Santisteban P (2020) ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity. *Oncogene* **39**: 3738–3753.
- Riedmann EM, Schopoff S, Hartner JC, and Jantsch MF (2000) Specificity of ADAR-mediated RNA editing in newly identified targets. *RNA*, **14**:1110–1118.
- Roundtree IA, Luo GZ, Zhang Z, Wang X, Zhou T, Cui Y, Sha J, Huang X, Guerrero L, Xie P, He E, Shen B, and He C (2017) YTHDC1 mediates nuclear export of N6-methyladenosine methylated mRNAs. *Elife* **6**.
- Ruby MA, Massart J, Hunerdosse DM, Schönke M, Correia JC, Louie SM, Ruas JL, Näslund E, Nomura DK, and Zierath JR (2017) Human carboxylesterase 2 reverses obesity-induced diacylglycerol accumulation and glucose intolerance. *Cell Rep* **18**: 636–646.

- Rybak-Wolf A, Stottmeister C, Glažar P, Jens M, Pino N, Giusti S, Behm M, Bartok O, Ashwal-Fluss R, Herzog M, Schreyer L, Papavasileiou P, Ivanov A, Öhman M, Refojo D, Kadener S, and Rajewsky N (2014) Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. *Mol Cell* **58**: 870–885.
- Schwartz S, Mumbach MR, Jovanovic M, Wang T, Maciag K, Bushkin GG, Mertins P, Ter-Ovanesyan D, Habib N, Cacchiarelli D, Sanjana NE, Freinkman E, Pacold ME, Satija R, Mikkelsen TS, Hacohen N, Zhang F, Carr SA, Lander ES, and Regev A (2014) Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5' sites. *Cell Rep* **8**: 284–296.
- Shi H, Wang X, Lu Z, Zhao BS, Ma H, Hsu PJ, Liu C, and He C (2017) YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA. *Cell Res* **27**: 315–328.
- Śledź P and Jinek M (2016) Structural insights into the molecular mechanism of the m6A writer complex. *Elife* **5**: e18434.
- Sommer B, Köhler M, Sprengel R, and Seeburg PH (1991) RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. *Cell* **67**: 11–19.
- Song C, Sakurai M, Shiromoto Y, and Nishikura K (2016) Functions of the RNA editing enzyme ADAR1 and their relevance to human diseases. *Genes (Basel)* **7**: 129.
- Sun Y, Fan J, Wang B, Meng Z, Ren D, Zhao J, Liu Z, Li D, Jin X, and Wu H (2020) The aberrant expression of ADAR1 promotes resistance to BET inhibitors in pancreatic cancer by stabilizing c-Myc. *Am J Cancer Res* **10**: 148–163.
- Takemoto S, Nakano M, Fukami T, and Nakajima M (2021) m⁶A modification impacts hepatic drug and lipid metabolism properties by regulating carboxylesterase 2. *Biochem Pharmacol* **193**: 114766.
- Takemoto S, Nakano M, Nozaki K, Fukami T, and Nakajima M (2021) Adenosine deaminases acting on RNA modulate the expression of the human pregnane X receptor. *Drug Metab Pharmacokinet* **37**: 100367.
- Takizawa M, Nakano M, Fukami T, and Nakajima M (2020) Decrease in ADAR1 expression by exposure to cigarette smoke enhances susceptibility to oxidative stress. *Toxicol Lett*

331: 22–32.

- Tang SJ, Shen H, An O, Hong HQ, Li J, Song Y, Han J, Tay DJT, Ng VHE, Bellido Molias F, Leong KW, Pitcheshwar P, Yang H, and Chen L (2020) Cis- and trans-regulations of pre-mRNA splicing by RNA editing enzymes influence cancer development. *Nat Commun* **11**: 1–17.
- Tariq A and Jantsch MF (2012) Transcript diversification in the nervous system: A to I RNA-editing in CNS function and disease development. *Front Neurosci* **6**: 99.
- Valente L and Nishikura K (2007) RNA binding-independent dimerization of adenosine deaminases acting on RNA and dominant negative effects of nonfunctional subunits on dimer functions. *J Biol Chem* **282**: 16054–16061.
- Wagner RW, Smith JE, Cooperman BS, and Nishikura K (1989) A double-stranded RNA unwinding activity introduces structural alterations by means of adenosine to inosine conversions in mammalian cells and *Xenopus* eggs. *Proc Natl Acad Sci USA* **86**: 2647–2651.
- Wang P, Doxtader KA, and Nam Y (2016) Structural Basis for Cooperative Function of Mettl3 and Mettl14 Methyltransferases. *Mol Cell* **63**: 306–317.
- Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, Fu Y, Parisien M, Dai Q, Jia G, Ren B, Pan T, and He C (2014) N 6-methyladenosine-dependent regulation of messenger RNA stability. *Nature* **505**: 117–120.
- Warda AS, Kretschmer J, Hackert P, Lenz C, Urlaub H, Höbartner C, Sloan KE, and Bohnsack MT (2017) Human METTL16 is a N 6 -methyladenosine (m 6 A) methyltransferase that targets pre-mRNAs and various non-coding RNAs . *EMBO Rep* **18**: 2004–2014.
- Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, and Ball SE (2004) Drug-drug interactions for UDP-glucuronosyltransferase substrates: A pharmacokinetic explanation for typically observed low exposure (AUC_i/AUC) ratios. *Drug Metab Dispos* **32**: 1201–1208.
- Xiang JF, Yang Q, Liu CX, Wu M, Chen LL, and Yang L (2018) N6-Methyladenosines Modulate A-to-I RNA Editing. *Mol Cell* **69**: 126–135.

- Xiao P, Liu YK, Han W, Hu Y, Zhang BY, and Liu WL (2021) Exosomal delivery of FTO confers gefitinib resistance to recipient cells through ABCC10 regulation in an m6a-dependent manner. *Mol Cancer Res* **19**: 726–738.
- Xiao W, Adhikari S, Dahal U, Chen YS, Hao YJ, Sun BF, Sun HY, Li A, Ping XL, Lai WY, Wang X, Ma HL, Huang CM, Yang Y, Huang N, Jiang G Bin, Wang HL, Zhou Q, Wang XJ, Zhao YL, and Yang YG (2016) Nuclear m6A reader YTHDC1 regulates mRNA plicing. *Mol Cell* **61**: 507–519.
- Xie W, Ma LL, Xu YQ, Wang BH, and Li SM (2019) METTL3 inhibits hepatic insulin sensitivity via N6-methyladenosine modification of Fasn mRNA and promoting fatty acid metabolism. *Biochem Biophys Res Commun* **518**: 120–126.
- Xu L-D and Öhman M (2018) ADAR1 Editing and its Role in Cancer. *Genes* **10**: 12.
- Xuan JJ, Sun WJ, Lin PH, Zhou KR, Liu S, Zheng LL, Qu LH, and Yang JH (2018) RMBase v2.0: Deciphering the map of RNA modifications from epitranscriptome sequencing data. *Nucleic Acids Res* **46**: D327–D334.
- Yan F, Al-Kali A, Zhang Z, Liu J, Pang J, Zhao N, He C, Litzow MR, and Liu S (2018) A dynamic N 6-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. *Cell Res* **28**: 1062–1076.
- Zanger UM, and Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacol Ther* **138**: 103–141.
- Zhang J, Bai R, Li M, Ye H, Wu C, Wang C, Li S, Tan L, Mai D, Li G, Pan L, Zheng Y, Su J, Ye Y, Fu Z, Zheng S, Zuo Z, Liu Z, Zhao Q, Che X, Xie D, Jia W, Zeng MS, Tan W, Chen R, Xu RH, Zheng J, and Lin D (2019) Excessive miR-25-3p maturation via N 6 -methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. *Nat Commun* **10**: 1–15.
- Zhang SY, Zhang SW, Zhang T, Fan XN, and Meng J (2021) Recent advances in functional annotation and prediction of the epitranscriptome. *Comput Struct Biotechnol J* **19**: 3015–3026.

- Zheng G, Dahl John Arne, Niu Y, Fedorcsak P, Huang C-M, Li CJ, Vågbø CB, Shi Y, Wang WL, Song SH, Lu Z, Bosmans RPG, Dai Q, Hao YJ, Yang X, Zhao WM, Tong WM, Wang XJ, Bogdan F, Furu K, Fu Y, Jia G, Zhao X, Liu J, Krokan HE, Klungland A, Yang YG, and He C (2013) ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. *Mol Cell* **49**: 18–29.
- Zhong X, Yu J, Frazier K, Weng X, Li Y, Cham CM, Dolan K, Zhu X, Hubert N, Tao Y, Lin F, Martinez-Guryn K, Huang Y, Wang T, Liu J, He C, Chang EB, and Leone V (2018) Circadian clock regulation of hepatic lipid metabolism by modulation of m6A mRNA methylation. *Cell Rep* **25**: 1816-1828.
- Zipeto MA, Court AC, Sadarangani A, Delos Santos NP, Balaian L, Chun HJ, Pineda G, Morris SR, Mason CN, Geron I, Barrett C, Goff DJ, Wall R, Pellicchia M, Minden M, Frazer KA, Marra MA, Crews LA, Jiang Q, and Jamieson CHM (2016) ADAR1 activation drives leukemia stem cell self-renewal by impairing let-7 biogenesis. *Cell Stem Cell* **19**: 177–191.

Footnotes

This paper was supported by a Grant-in-Aid for Scientific Research (B) [18H02573/21H02624], a Grant-in-Aid for Scientific Research (C) [20K07013] and a Grant-in-Aid for Early Career Scientists [18K14901] from the Japan Society for the Promotion of Science, Takeda Science Foundation, The Naito Foundation, and World Premier International Research Center Initiative (WPI), MEXT, Japan.

The authors declare that they have no conflicts of interest with the contents of this article.

Figure legends

Figure 1. Functional significance of A-to-I RNA editing. Adenosine deaminase acting on RNA (ADAR) enzymes converts adenosine to inosine by hydrolytic deamination. Inosine is recognized by the cellular machinery as if it were guanosine. Through nucleotide conversion, amino acid sequence, splicing, microRNA (miRNA) processing, and miRNA targeting can change. UTR, untranslated region.

Figure 2. A-to-I RNA editing modulating drug metabolism-related genes. ADAR1 and ADAR2 positively regulate hepatocyte nuclear factor 4 α (HNF4 α) by promoting translation, leading to upregulation of CYP2C8 expression. ADAR1 negatively regulates aryl hydrocarbon receptor (AhR) by creating a miRNA binding element, leading to downregulation of CYP1A2 expression. ADAR1 negatively regulates constitutive androstane receptor (CAR) by attenuating splicing, leading to downregulation of CYP2B6 and CYP3A4 expression. ADAR1 and ADAR2 downregulate pregnane X receptor (PXR) by facilitating mRNA degradation, leading to downregulation of CYP3A4 expression. Arnt, aryl hydrocarbon receptor nuclear translocator; RXR α , retinoid X receptor α .

Figure 3. Functional significance of m⁶A modification. m⁶A is installed by a methyltransferase complex such as methyltransferase-like 3 (METTL3) and METTL14, which are called “m⁶A writers”, whereas the methyl group can be removed by RNA demethylases including fat mass and obesity-associated (FTO) and AlkB homolog 5 (ALKBH5), which are called “m⁶A erasers”. As an “m⁶A reader”, YTHDF1 promotes the translation efficiency of m⁶A-modified mRNA. YTHDF2 and YTHDC2 enhance the degradation of m⁶A-modified mRNA. YTHDC1 mediates splicing of m⁶A-containing mRNA. YTH, YT521-B homology.

Figure 4. m⁶A modification modulating drug metabolism-related genes. CYP2C8 mRNA is subjected to m⁶A modification, leading to YTHDC2-mediated degradation of its mRNA. m⁶A

modification negatively regulates UGT2B7 expression by downregulating HNF4 α . YTHDC2 promotes degradation of CES2 mRNA by recognizing m⁶A in the 5'-UTR. CES, carboxylesterase; CYP, cytochrome P450; UGT, UDP-glucuronosyltransferase.

Table 1. Drug metabolism-related genes whose mRNA is subjected to A-to-I RNA editing and expression is regulated by ADARs

Gene	A-to-I RNA edited region		Effects, ADARs, cell line	Reference
	Evaluation by NGS ¹	Evaluation by Sanger sequencing		
CYP1A2	Intron, 3'-UTR	ND	Up-regulation, ADAR2, HepaRG cells	Nozaki et al., 2019
CYP2A6	Intron	ND	Up-regulation, ADAR1 and ADAR2, HepaRG cells	Nozaki et al., 2019
CYP2B6	Intron, 3'-UTR	Not edited in 3'-UTR	Up-regulation, ADAR1 and ADAR2, HepaRG cells	Nozaki et al., 2019
CYP2C8	5'-UTR, intron	ND	Up-regulation, ADAR1 and ADAR2, HepaRG cells	Nozaki et al., 2019
CYP2C9	Intron, 3'-UTR	ND	Up-regulation, ADAR1 and ADAR2, HepaRG cells	Nozaki et al., 2019
CYP2C19	3'-UTR	ND	Up-regulation, ADAR1 and ADAR2, HepaRG cells	Nozaki et al., 2019
CYP2D6	Coding region	ND	Up-regulation, ADAR2, HepaRG cells	Nozaki et al., 2019
CYP2E1	Intron	ND	Up-regulation, ADAR1 and ADAR2, HepaRG cells	Nozaki et al., 2019
CYP3A4	Intron, 3'-UTR	Not edited in 3'-UTR	Down-regulation, ADAR1, HepaRG and HepG2 cells	Nozaki et al., 2019 Takemoto et al., 2021
UGT1A	Intron, 3'-UTR	ND	Down-regulation, ADAR1, HepG2 cells	Takemoto et al., 2021
UGT2B4	Intron	ND	ND	
UGT2B15	Intron	ND	ND	
UGT2B17	Intron	ND	ND	
CES1	Intron	ND	ND	
CES2	5'-UTR, intron	ND	ND	
AhR	3'-UTR	Edited in 3'-UTR	Down-regulation, ADAR1, Huh-7 cells	Nakano et al., 2016
CAR	Intron	Not edited in 3'-UTR	Down-regulation, ADAR1, HepG2 cells	Nakano et al., 2019
HNF4 α	Intron	ND	Up-regulation, ADAR1 and ADAR2, HepaRG and Huh-7 cells	Nozaki et al., 2019
PXR	Intron	Not edited in 3'-UTR	Down-regulation, ADAR1 and ADAR2, HepaRG and HepG2 cells	Takemoto et al., 2021

¹REDIportal (<http://srv00.recas.ba.infn.it/atlas/>), a database of A-to-I RNA editing sites identified by NGS.

ND, no data; NGS, next-generation sequencing.

Table 2. Drug metabolism-related genes whose mRNA is subjected to m⁶A modification and whose expression is regulated by m⁶A-related enzymes

Gene	m ⁶ A modified region Evaluation by NGS ¹	Evaluation by RIP with anti-m ⁶ A antibody	Effects, m ⁶ A-related enzymes, cell line	Reference
CYP2B6	3'-UTR	ND	ND	Nakano et al., 2020
CYP2C8	Coding region, 3'-UTR	Modified in 5'-UTR, coding region, and 3'-UTR	Down-regulation, METTL3/14; up-regulation, FTO; down-regulation, YTHDC2, HepaRG and Huh-7 cells	
UGT1A	Coding region, intron, 3'-UTR	ND	ND	
UGT2B4	Coding region	ND	ND	
UGT2B7	Not registered	Modified in 5'-UTR, coding region, and 3'-UTR	Down-regulation, METTL3/14; up-regulation, FTO and ALKBH5, Huh-7 cells	Ondo et al., 2021
UGT2B15	Coding region	ND	ND	
UGT2B17	Intron	ND	ND	
CES1	5'-UTR, coding region	ND	ND	
CES2	5'-UTR, coding region, intron, 3'-UTR	Modified in 5'-UTR, coding region, and 3'-UTR	Down-regulation, METTL3/14; up-regulation by FTO and ALKBH5; down-regulation by YTHDC2, HepaRG and Huh-7 cells	Takemoto et al., 2021
AhR	5'-UTR, coding region, 3'-UTR	ND	ND	
CAR	Coding region, intron, 3'-UTR	ND	ND	
HNF4α	3'-UTR	Modified in 5'-UTR, coding region, and 3'-UTR	Up-regulation, FTO, Huh-7 cells	
PXR	Coding region, 3'-UTR	ND	ND	Ondo et al., 2021

¹RMBase (<https://rna.sysu.edu.cn/rmbase/index.php>), a database of m⁶A modification sites identified by NGS.

ND, no data; NGS, next-generation sequencing; RIP, RNA immunoprecipitation.

Figure 1

Figure 2

Figure 3

Figure 4